US Patent No: 6,881,829

Number of patents in Portfolio can not be more than 2000

Chimeric hybrid analgesics

Stats

ALSO PUBLISHED AS: 20030202981
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention provides composition of matter for and methods of treating pain and drug abuse using novel chimeric hybrid molecules containing an opioid moiety of chemically modified morphine (3) that binds to and activates the human mu (.mu.) opioid receptor, with the opioid moiety linked through a novel linker-hinge (4) to a substance P peptide fragment moiety (5) that binds to and activates the human substance P receptor. The hybrid alkaloid/peptide chimeric molecules produce clinically efficacious opioid analgesia with little or no development of opioid tolerance or formation of opioid dependence. The hybrid alkaloid/peptide analgesics may be administered intrathecally, systemically or orally.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
CHIMERACOM, LLCNEW YORK, NY2

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kream, Richard M Huntington, NY 5 30

Cited Art

Patent Info (Count) # Cites Year
 
ADVANCED TARGETING SYSTEMS, INC. (1)
6,063,758 Substance P-Saporin (SP-SAP) conjugates and methods of use thereof 12 1997
 
THE LYNX PROJECT LIMITED (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 23 1997
 
TRUSTEES OF TUFTS COLLEGE (1)
5,891,842 Methodology for eliciting an analgesic response in a living subject 25 1996

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
CHIMERACOM, LLC (1)
7,214,657 Method of transporting a chimeric hybrid molecule across the blood brain barrier 0 2003
 
UNIVERSITY OF ARIZONA (1)
8,026,218 Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists 0 2007

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 19, 2016
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00